




Best Practice Examples

Experiences with PEI in ATMP development

HOW SCIENTISTS SEE THE AUTHORITIES

Slide © Vuk Savkovic, Universität Leipzig



A JOURNEY TO MORDOR?



Overview

- Scientific Advice
- Experiences with PEI
- Q&A

No discussion of other counselling formats

WHAT YOU GET AND WHAT YOU DON'T



NO APPROVAL

You get advice and a «positive quote», but no approval!



CHANGE OF MIND

PEI can change their opinion.
State of the art can change.
→ «The Hobbit or There and Back Again»



CLEAR PATH

Often not the easiest way, but you actually know what to do.



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf?_blob=publicationFile&v=6





APPLICATION

- Topics
- Number of participants
- Appointment requests
- Question form: «Does PEI agree that ...?»
- Form on PEI website



BRIEFING DOCUMENT

- \leq 40 pages + attachments
- Summarizing questions and your own position
- Detailed supportive evidence for your own argumentation



PRESENTATION



DRAFT PROTOCOL

- Take someone to the consultation who can write quickly, ideally quotes.
- Write what you hope for (in accordance with the consultation, of course)



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf? blob=publicationFile&v=6

-4 Months

GENERAL

APPLICANT CONTACT PERSON AREA OF MEDICINAL PRODUCT ATMP

MEDICINAL PRODUCT

Name of the medicinal product and of the active substance(s)

Therapeutic indication

Short description of key manufacturing steps

Short description of the mode of action respectively the effect of the medicinal product



APPLICATION

- Topics
- Number of participants
- Appointment requests
- Question form: «Does PEI agree that ...?»
- Form on PEI website

JOINT SCIENTIFIC ADVICE



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf?_blob=publicationFile&v=6 -4 Months

MEDICINAL PRODUCT

Name of the medicinal product and of the active substance(s)

Therapeutic indication

Short description of key manufacturing steps

Short description of the mode of action respectively the effect of the medicinal product

SCOPE OF THE SCIENTIFIC ADVICE

Quality Viral safety Microbiological safety Non-clinic Clinic



APPLICATION

- Topics
- Number of participants
- Appointment requests
- Question form: «Does PEI agree that ...?»
- Form on PEI website

Biostatistics

Procedural issues

Paediatric indication

Not clearly stated that the questions should be asked now, but you may be asked to submit them later.



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form: https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf? blob=publicationFile&v=6

-4 Months

Quality Viral safety Microbiological safety Non-clinic Clinic

ADDITIONAL INFORMATION

Objectives of the advice **Preferred dates** Number of participants Some formal aspects



APPLICATION

- Topics
- Number of participants
- Appointment requests
- Question form: «Does PEI agree that ...?»
- Form on PEI website

SCOPE OF THE SCIENTIFIC ADVICE

Biostatistics

Procedural issues

Paediatric indication



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf?_blob=publicationFile&v=6

-4 Months SCHEDULING -3 Months



APPLICATION

- Topics
- Number of participants
- Appointment requests
- Question form: «Does PEI agree that ...?»
- Form on PEI website



BRIEFING DOCUMENT

- \leq 40 pages + attachments
- Summarizing questions and your own position
- Detailed supportive evidence for your own argumentation



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf? blob=publicationFile&v=6

-3 Months

RECOMMENDATION

IMPD FORM

QUESTIONS AND APPLICANT'S POSITIONS

Question 1: Does PEI agree ...? Applicant's position: ...

PAY ATTENTION TO EVERY SENTENCE

ANNEXES

Only supportive (e.g., raw data)




FOR YOURSELVES



BRIEFING DOCUMENT

- \leq 40 pages + attachments
- Summarizing questions and your own position
- Detailed supportive evidence for your own argumentation



THIS IS PROBABLY THE MOST IMPORTANT WORK YOU DO




DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf? blob=publicationFile&v=6





BRIEFING DOCUMENT

- \leq 40 pages + attachments
- Summarizing questions and your own position
- Detailed supportive evidence for your own argumentation



PRESENTATION

••••••

DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf?__blob=publicationFile&v=6

-3 Months -1 Week **SCIENTIFIC ADVICE**



BRIEFING DOCUMENT

- \leq 40 pages + attachments
- Summarizing questions and your own position
- Detailed supportive evidence for your own argumentation



PRESENTATION



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf? blob=publicationFile&v=6

SCIENTIFIC ADVICE

PREPARATION

REHAERSAL

Pay attention to every sentence

Use notes, if necessary

CONSULTATION

Now: Online

PEI interrupts the presentation for questions \rightarrow Encourage them to do so at the beginning

NOTES FOR PROTOCOL



KEEP IN MIND:

YOU are the experts about your product. PEI is not all-knowing.





Take someone to the consultation who can write quickly, ideally quotes



DEADLINES, PROCEDURE, APPLICATION, AND PREPARATION

Since February 2024, templates and a list of do's & don'ts have been available on the PEI website for all documents.

https://www.pei.de/DE/regulation/beratung/beratungsformate/berat ungsformate-node.html

Application form:

https://www.pei.de/SharedDocs/Downloads/DE/regulation/beratung /innovationsbuero/formularfirmenberatung.pdf?__blob=publicationFile&v=6






DRAFT PROTOCOL

- Take someone to the consultation who can write quickly, ideally quotes.
- Write what you hope for (in accordance with the consultation, of course)

OUR CASE ATMP PALINTRA®




CHALLENGES



 Short shelf life Decentralised Manufacture • Who is the Manufacturer (German: PU)? • Approval of antibody or ATMP or antibody as starting material for ATMP manufacture or ...?

TOPICS SCIENTIFIC CONSULTATIONS WITH PEI

2017 until 2023



Early-Stage Development Regulatory advice on authorisation

Nonclinical Development & Synopsis Clinical Development

Nonclinical Development & Development/Validation ATIMP Manufacturing Process



Change in ATIMP manufacturing process and resulting change in nonclinical development

© Lilly Stahl | Tcell Tolerance GmbH | 2024

•••



Why it is important

- Preparation process: To summarise all you know about your product
- Clear picture («Fakten schaffen»): Are your marketing authorization ideas sustainable?

OUR EXPERIENCES



EARLY-STAGE DEVELOPMENT REGULATORY ADVICE ON AUTHORISATION

• Aim: Only a few expensive nonclinical GLP experiments ightarrow Months of research for old data in dusty archives (supportive safety evidence) \rightarrow PEI: «This data is not relevant.»

Write a review article.



Why it is important

- Preparation process: To summarise all you know about your product
- Clear picture («Fakten schaffen»): Are your marketing authorization ideas sustainable?

OUR EXPERIENCES



EARLY-STAGE DEVELOPMENT REGULATORY ADVICE ON AUTHORISATION

The person who was supposed to give the presentation was admitted to hospital one day before departure

Have a back-up!



Why it is important

- Preparation process: To summarise all you know about your product
- Clear picture («Fakten schaffen»): Are your marketing authorization ideas sustainable?

OUR EXPERIENCES

EARLY-STAGE DEVELOPMENT REGULATORY ADVICE ON AUTHORISATION

Detailed questions on data in the annexes

Take someone with you who actually knows the experiments.



Why it is important

- Preparation process: To summarise all you know about your product
- Clear picture («Fakten schaffen»): Are your marketing authorization ideas sustainable?

EARLY-STAGE DEVELOPMENT REGULATORY ADVICE ON AUTHORISATION

OUR EXPERIENCES



• At that time no regulation for our case

 \rightarrow PEI: Guideline on non-substantially manipulated ATMPs \rightarrow PhD student asked:

What ist that? Never heard about it.

 \rightarrow PEI: Of course not, the draft is not public yet. But you can get it from us afterwards.

Take someone with you who does not lose face when he/she asks «stupid» questions.



Why it is important

- Preparation process: To summarise all you know about your product
- Clear picture («Fakten schaffen»): Are your marketing authorization ideas sustainable?

EARLY-STAGE DEVELOPMENT REGULATORY ADVICE ON AUTHORISATION

OUR EXPERIENCES



Scheduled: 2 hrs, ended after 1:40 hrs \rightarrow Withdrawn question on clinical trial design was asked (open form)

> Asking open questions can end well but is **NOT recommended.**

SECOND SCIENTIFIC ADVICE



Why it is important

- Positive vote for your nonclinical development plan
- IMPD form

OUR EXPERIENCES

NONCLINICAL DEVELOPMENT SYNOPSIS CLINICAL DEVELOPMENT

Accomodation costs + costs for vendor ightarrow Now: Online Meetings \rightarrow Cost-effective and time-saving

SECOND **SCIENTIFIC ADVICE**



Why it is important

- Positive vote for your nonclinical development plan
- IMPD form

- Unexpected (and incorrect) opinion that stem cells bear CD4 \rightarrow Although we knew better, no disagreement in the consultation
 - \rightarrow Literature study and additional experiments in



NONCLINICAL DEVELOPMENT SYNOPSIS CLINICAL DEVELOPMENT

OUR EXPERIENCES

preparation for the next SA

Take someone with you who does not lose face when he/she asks «stupid» questions.

SECOND SCIENTIFIC ADVICE



Why it is important

- Positive vote for your nonclinical development plan
- IMPD form

NONCLINICAL DEVELOPMENT SYNOPSIS CLINICAL DEVELOPMENT

OUR EXPERIENCES

PEI wanted extended nonclinical development plan

Homework for 3rd SA

THIRD SCIENTIFIC ADVICE



Why it is important

- Positive vote for your nonclinical development plan
- Positive vote for the ATIMP manufacture process development & validation plan
- IMPD form

OUR EXPERIENCES

plan

PEI is also subject to inspection by the animal welfare authorities.

NONCLINICAL DEVELOPMENT **DEVELOPMENT/VALIDATION ATIMP MANUFACTURING PROCESS**

PEI reduced the proposed extended nonclinical development

FOURTH **SCIENTIFIC ADVICE**



Why it is important

- Positive vote for your nonclinical development plan
- Positive vote for the ATIMP manufacture process development & validation plan
- IMPD form

PROCESS

OUR EXPERIENCES



CHANGE IN ATIMP MANUFACTURING

RESULTING CHANGE IN NONCLINICAL DEVELOPMENT

CHANGE OF MIND

• PEI: Old data is supportive safety evidence PEI: Absolute quantifiers (3rd SA they wanted relative quantifiers)

Homework for IMPD

A JOURNEY TO MORDOR?







WHAT I LEARNED

Reading guidelines is very interesting

Disillusionment with research articles

Keep asking stupid questions



Tolerance







Tcell Tolerance GmbH Karl-Tauchnitz-Straße 8 04107 Leipzig



+49 341 331572-47



I.stahl@tcell-tolerance.de



https://tcell-tolerance.de